Anticoagulation techniques in apheresis: From heparin to citrate and beyond

Journal of Clinical Apheresis

Volumn 27, Issue 3, 2012, Pages 117-125

  Lee, Grace ^a   Arepally, Gowthami M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulation; apheresis; citrate; heparin; hypocalcemia

Indexed keywords

ACID CITRATE DEXTROSE; CALCIUM CHLORIDE; CALCIUM ION; CITRIC ACID; FRESH FROZEN PLASMA; GLUCONATE CALCIUM; GLUCOSE; HEPARIN; PARATHYROID HORMONE;

ABDOMINAL CRAMP; ACID BASE BALANCE; ANTICOAGULATION; APHERESIS; BLOOD VOLUME; CALCIUM BLOOD LEVEL; COMORBIDITY; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DYSESTHESIA; ELECTROLYTE DISTURBANCE; ERYTHROCYTE; FLUSHING; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ARRHYTHMIA; HEART FUNCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; IRRITABILITY; METABOLIC ALKALOSIS; MUSCLE SPASM; NAUSEA AND VOMITING; NERVOUSNESS; PARATHYROID HORMONE BLOOD LEVEL; PARESTHESIA; PHARMACOLOGY; PHLEBOTOMY; PLASMAPHERESIS; PUVA; RISK FACTOR; SEIZURE; SHIVERING; SNEEZING; SYSTEMIC CIRCULATION; TETANY; TREMOR; VITAMIN SUPPLEMENTATION;

ANTICOAGULANTS; BLOOD COMPONENT REMOVAL; CALCIUM; CITRIC ACID; HEMORRHAGE; HEPARIN; HUMANS; HYPOCALCEMIA; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84861825318     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21222     Document Type: Conference Paper

References (61)

1. Mollison PL,. The introduction of citrate as an anticoagulant fortransfusion and of glucose as a red cell preservative. Br J Haematol 2000; 108: 13-18.
2. Carlon GC, Howland WS, Goldiner PL, Kahn RC, Bertoni G, Turnbull AD,. Adverse effects of calcium administration. Report of two cases. Arch Surg 1978; 113: 882-885.
3. Strauss RG,. Mechanisms of adverse effects during hemapheresis. J Clin Apher 1996; 11: 160-164.
4. Hastings AB MF, Eichelberger L, Hall Jl, Da Costa E,. The ionization of calcium, magnesium, and strontium citrates. J Biol Chem 1934; 107: 351-370.
5. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS,. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 1996; 27: 519-524.
6. Ludbrook J, Wynn V,. Citrate intoxication; a clinical and experimental study. Br Med J 1958; 2: 523-528.
7. Farrokhi P, Farahmand H, Bismuth A, et al. How to stabilize the level of ionized calcium and citrate during plateletpheresis. Vox Sang 1998; 74: 7-12.
8. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455.
9. Kishimoto M, Ohto H, Shikama Y, Kikuta A, Kimijima I, Takenoshita S,. Treatment for the decline of ionized calcium levels during peripheral blood progenitor cell harvesting. Transfusion 2002; 42: 1340-1347.
10. Marques MB, Huang ST,. Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apher 2001; 16: 120-124.
11. Hester JP, McCullough J, Mishler JM, Szymanski IO,. Dosage regimens for citrate anticoagulants. J Clin Apher 1983; 1: 149-157.
12. Crookston KP, Novak DJ,. Physiology of Apheresis. In:, McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL, editors. Apheresis: Principles and Practice. Bethesda, MD: AABB Press. 2010. pp 45-69.
13. Ladenson JH, Miller WV, Sherman LA,. Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood. Transfusion 1978; 18: 670-679.
14. Weinstein R,. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apher 1996; 11: 204-210.
15. Hester JP, Ayyar R,. Anticoagulation and electrolytes. J Clin Apher 1984; 2: 41-51.
16. Penny A,. Plasmapheresis procedure design operation: a consideration of citrate anticoagulant usage. Transfus Sci 1989; 10: 51-56.
17. Uhl L, Maillet S, King S, Kruskall MS,. Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 1997; 37: 1063-1065.
18. Crocco A, D'Elia D,. Adverse reactions during voluntary donation of blood and/or blood components. A statistical-epidemiological study. Blood Transfus 2007; 5: 143-152.
19. Rodnitzky RL, Goeken JA,. Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39: 350-354.
20. Buchta C, Macher M, Bieglmayer C, Hocker P, Dettke M,. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 2003; 43: 1615-1621.
21. Winters JL,. Complications of donor apheresis. J Clin Apher 2006; 21: 132-141.
22. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611.
23. Korach JM, Petitpas D, Poiron L, Vincent N, Berger PH, Chillet P,. 14 years of therapeutic plasma exchange in France. Transfus Apher Sci 2001; 25: 73-77.
24. Bolan CD, Cecco SA, Wesley RA, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002; 42: 935-946.
25. Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF,. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001; 41: 1165-1171.
26. Toffaletti J, Nissenson R, Endres D, McGarry E, Mogollon G,. Influence of continuous infusion of citrate on responses of immunoreactive parathyroid hormone, calcium and magnesium components, and other electrolytes in normal adults during plateletapheresis. J Clin Endocrinol Metab 1985; 60: 874-879.
27. Urban P, Scheidegger D, Buchmann B, Barth D,. Cardiac arrest and blood ionized calcium levels. Ann Internal Med 1988; 109: 110-113.
28. Bolan CD, Cecco SA, Yau YY, et al. Randomized placebo-controlledstudy of oral calcium carbonate supplementation in plateletpheresis. II. Metabolic effects. Transfusion 2003; 43: 1414-1422.
29. Bolan CD, Wesley RA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis. I. Associations with donor symptoms. Transfusion 2003; 43: 1403-1413.
30. Nowak MA, Campbell TE,. Profound hypercalcemia in continuous veno-venous hemofiltration dialysis with trisodium citrate anticoagulation and hepatic failure. Clin Chem 1997; 43: 412-413.
31. Nagai Y, Itabashi M, Mizutani M, et al. A case report of uncompensated alkalosis induced by daily plasmapheresis in a patient with thrombotic thrombocytopenic purpura. Ther Apher Dial 2008; 12: 86-90.
32. Pearl RG, Rosenthal MH,. Metabolic alkalosis due to plasmapheresis. Am J Med 1985; 79: 391-393.
33. Smith RM,. Blood replacement in thoracic surgery for children. J Am Med Assoc 1956; 161: 1124-1128.
34. Wirguin I, Brenner T, Shinar E, Argov Z,. Citrate-induced impairment of neuromuscular transmission in human and experimental autoimmune myasthenia gravis. Ann Neurol 1990; 27: 328-330.
35. Humpe A, Riggert J, Munzel U, Kohler M,. A prospective, randomized, sequential crossover trial of large-volume versus normal-volume leukapheresis procedures: effects on serum electrolytes, platelet counts, and other coagulation measures. Transfusion 2000; 40: 368-374.
36. Schlenke P, Frohn C, Steinhardt MM, Kirchner H, Kluter H,. Clinically relevant hypokalaemia, hypocalcaemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apher 2000; 15: 230-235.
37. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z,. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005; 9: 391-395.
38. Rock G, Sutton DM,. Apheresis: man versus machine. Transfusion 1997; 37: 993-995.
39. Antonic M, Gubensek J, Buturovic-Ponikvar J, Ponikvar R,. Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial 2009; 13: 322-326.
40. Juan D,. Hypocalcemia. Differential diagnosis and mechanisms. Arch Intern Med 1979; 139: 1166-1171.
41. Moog R,. Adverse events in peripheral progenitor cell collection: a 7-year experience. J Hematother Stem Cell Res 2001; 10: 675-680.
42. Reik RA, Noto TA, Fernandez HF,. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. JClin Apher 1997; 12: 10-13.
43. Passos-Coelho JL, Braine HG, Wright SK, et al. Large-volume leukapheresis using regional citrate anticoagulation to collect peripheral blood progenitor cells. J Hematother 1995; 4: 11-19.
44. Laspina SJ, Browne MA, McSweeney EN, et al. QTc prolongation in apheresis platelet donors. Transfusion 2002; 42: 899-903.
45. Furman RA, Hellerstein HK, Startzman VV,. Electrocardiographic changes occurring during the course of replacement transfusions. J Pediatr 1951; 38: 45-50.
46. Pinnick RV, Wiegmann TB, Diederich DA,. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983; 308: 258-261.
47. van der Meulen J, Janssen MF, Oe PL,. Cardiac arrest during rapid plasma exchange for haemolytic uraemic syndrome. Nephrol Dial Transplant 1994; 9: 1841.
48. Bunker JP, Bendixen HH, Murphy AJ,. Hemodynamic effects of intravenously administered sodium citrate. N Engl J Med 1962; 266: 372-377.
49. Olson PR, Cox C, McCullough J,. Laboratory and clinical effects of the infusion of ACD solution during plateletpheresis. Vox Sang 1977; 33: 79-87.
50. AHA. Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities. Circulation 2005; 112: IV-121-IV-5.
51. Broner CW, Stidham GL, Westenkirchner DF, Watson DC,. A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. J Pediatr 1990; 117: 986-989.
52. Bastin G,. The use of constant calcium infusion reduces side effects in high-yield platelet apheresis (abstract). J Clin Apher 1993; 8: 32.
53. Mercan D, Bastin G, Lambermont M, Dupont E,. Importance of ionized magnesium measurement for monitoring of citrate-anticoagulated plateletpheresis. Transfusion 1997; 37: 418-422.
54. Perseghin P, Confalonieri G, Buscemi F, et al. Electrolyte monitoring in patients undergoing peripheral blood stem cell collection. J Clin Apher 1999; 14: 14-17.
55. Diaz MA, Garcia-Sanchez F, Lillo R, Vicent MG, Vicario JL, Madero L,. Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. Haematologica 1999; 84: 32-35.
56. Kim HC,. Therapeutic pediatric apheresis. J Clin Apher 2000; 15: 129-157.
57. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI,. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S-159S.
58. Schulman S, Beyth RJ, Kearon C, Levine MN,. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S-298S.
59. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC,. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145-150.
60. Arepally G, Ortel TL,. Heparin-induced thrombocytopenia. N Eng J Med 2006; 355: 809-817.
61. Kankirawatana S, Huang ST, Marques MB,. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. JClin Apher 2007; 22: 265-269.